www.smccro-lab.com Open in urlscan Pro
13.57.237.40  Public Scan

Form analysis
0 forms found in the DOM

Text Content

This website stores cookies on your computer. These cookies are used to collect
information about how you interact with our website and allow us to remember
you. We use this information in order to improve and customize your browsing
experience and for analytics and metrics about our visitors both on this website
and other media. To find out more about the cookies we use, see our Privacy
Policy.Learn more

OK

 * HOME
 * 2 ABOUT US
   
 * 4 PRODUCTS & SERVICES
 * 3 CSR
 * NEWS
 * CONTACT
 * SITEMAP
 * PRIVACY POLICY
 * RECRUIT
 * JAPANESE
 * × CLOSE MENU

ABOUT US
 * COMPANY DATA
 * ACCESS

PRODUCTS & SERVICES
 * SMC QUALITY
 * 3 SERVICE
 * 2 MODEL CASE
 * PUBLICATION RECORDS

SERVICE
 * CRO & Consulting Service Info.
 * Histology
 * Trial

MODEL CASE
 * Therapeutic areas
 * 14 Disease area

Disease area
 * STAM™
 * Bleomycin-induced pulmonary fibrosis
 * Porcine Pancreatic Elastase (PPE) model
 * CCl4-induced liver fibrosis model
 * Bile duct ligation (BDL) model
 * CCl4-induced acute liver failure model
 * UUO-induced renal fibrosis model
 * Adriamycin-induced nephropathy model
 * DSS-induced colitis model
 * icv-STZ model
 * Bleomycin-induced skin fibrosis model
 * Fatty Liver/ NAFLD　MCD model　/Methionine and choline difcient model
 * DEN-CCl4 liver cancer model
 * Xenograft tumor models

CSR
 * SDGs
 * ANIMAL WELFARE BY SMC Laboratories
 * CONTRIBUTING TO THE LOCAL COMMUNITY

 * GLOBAL
 * JAPANESE
 * 
 * 
 * 

MENU



DISEASE AREA

このスペースに"Products & Services"についての説明文を記載できればと考えております。

 * HOME
   
 * PRODUCT & SERVICE
 * MODEL CASE
 * DISEASE AREA
 * STAM™ MODEL
   


STAM™ MODEL

Our STAM™ model is a model that recapitulates the same disease progression as
human NASH/HCC. In this model, male C57BL/6 mice aged two days are given a
single dose of streptozotocin to reduce insulin secretory capacity. When the
mice turn four weeks of age they start a high-fat diet feeding. This model has a
background of late type 2 diabetes which progresses into fatty liver, NASH,
fibrosis and consequently liver cancer (HCC). Compared to other NASH-HCC model
mice, the disease progresses in a relatively short period of time, and liver
cancer is developed in 100% of animals at 20 weeks of age.Thus, our model is
widely used in NASH research, with more than 70 papers (seen left of the figure
shown below) and 80 international conferences (listed right of the figure shown
below) published using data from our STAM™ model so far.

 * Publications
   
   

 * Presentations
   
   

Our STAM™ model is able to reproduce many of the pathological features of human
NASH.
For example

 * Ballooning degeneration of cells, a characteristic pathological feature of
   human NASH.
 * Burned-out NASH, in which lipid droplets decrease as fibrosis progresses.
 * Progression of fibrosis occuring around the central vein.
 * A mild rise in ALT (a liver injury marker).
 * Increase in NASH markers such as CK-18.
 * Increase in human HCC markers such as: glutamine synthase, glypican-3 and AFP
   have been observed.

Recently, a comprehensive analysis of genomics, transcriptomics (Dow, M., et al)
and lipidomics (Saito. K. et al) from domestic and international academia has
demonstrated the high clinical correlation of our STAM model. There are 15 test
substances that have entered the clinical stage using data from STAM model
pharmacology studies, and are now showing efficacy against NASH

 * View a flyer

 * Page back



STAM™ Model
CONTACT
 * ABOUT US COMPANY DATA ACCESS
 * PRODUCTS & SERVICES SMC QUALITY SERVICE MODEL CASE PUBLICATION RECORDS
 * CSR SDGs ANIMAL WELFARE BY
   SMC Laboratories CONTRIBUTING TO THE LOCAL COMMUNITY
   
 * HOME NEWS CONTACT SITEMAP PRIVACY POLICY RECRUIT

SMC Laboratories Inc.

Technoport Kamata Center Bldg. 2-16-1 Minami-Kamata Ota-City Tokyo, 144-0035
Japan
TEL +81-3-6715-9101


LA Office（USA）
20250 Acacia St. STE 240 Newport Beach, CA 92660
TEL：+1-949-756-8500




  





© 2019 SMC Laboratories,Inc. All rights reserved.

 * ABOUT US
   
    * COMPANY DATA
   
    * ACCESS

 * PRODUCTS & SERVICES
   
    * SMC QUALITY
   
    * 
      
      SERVICE CRO & Consulting
      Service Info. Histology Trial
   
    * 
      
      MODEL CASE Disease area Therapeutic areas
   
    * PUBLICATION RECORDS

 * CSR
   
    * SDGs
   
    * ANIMAL WELFARE BY
      SMC Laboratories
   
    * CONTRIBUTING TO THE
      LOCAL COMMUNITY

   
 * NEWS
 * CONTACT
 * HOME
   * RECRUIT
   * SITEMAP
   * PRIVACY POLICY

CONTACT US

▲PAGE TOP